Highest-materiality recent filing
Axe Compute files updated risk factors reflecting shift to owned GPU data center model
Company expands to own GPU hardware in data centers, shifting from asset-light model; expects significant capital expenditures for procurement and deployment.
Axe Compute signs $260M contract, Q1 net loss $7.7M, first compute revenue
$260M 36-month take-or-pay contract for 2,304 NVIDIA B300 GPUs; deployment Q3 2026, expected $21M/quarter revenue.
Axe Compute secures $260M, 3-year contract for 2,304 NVIDIA B300 GPUs; largest enterprise deal ever
Aggregate contract value of ~$260M over 36 months for dedicated GPU compute and high-speed storage.
Axe Compute reports $12M contract value, $835K/month income; names new President
$12M executed agreement value in last 30 days; 20+ enterprise customers, 30+ active deployments across AI/enterprise verticals.
Axe Compute reports FY2025 net loss of $232.9M; no compute revenue; holds $40M in ATH tokens
Total revenue $125,284, entirely from legacy Drug Discovery; no compute revenue in 2025.
Axe Compute terminates CEO Vennare; appoints Miglino as new CEO, grants 500K options
Raymond Vennare terminated without cause as CEO, effective Feb 9, 2026; receives $575k severance and $287.5k 2025 bonus.
Axe Compute loses two directors and CIO in January 2026
Shawn Matthews resigned as director effective Jan 15, 2026.
Company renamed Axe Compute Inc., now trades on Nasdaq under AGPU as of Dec 12, 2025.
Predictive Oncology regains Nasdaq minimum equity compliance; one-year monitor imposed
Received Nasdaq notice on Dec 1, 2025 confirming compliance with minimum $2.5M stockholders' equity requirement.
Predictive Oncology raises $343.5M via PIPE, regains Nasdaq equity compliance
Closed two PIPE transactions on Oct 7, 2025, receiving ~$343.5M total ($50.8M cash + ~$292.7M notional crypto assets valued at ~$173.3M discounted).
Predictive Oncology Q3 EPS loss $(107.24); records $74.4M derivative liability on ATH token strategy
Revenue of $3,618 virtually unchanged from $3,907 in Q3 2024; cash fell to $181,667 from $611,822 at Dec 31, 2024.
Predictive Oncology closes $343.5M private placements to launch digital asset treasury strategy
Raised ~$50.8M cash via 4.4M shares at $11.6265; plus ~$292.7M notional from in-kind ATH tokens.
Predictive Oncology launches private placements for cash and crypto, shifts to ATH token treasury
Cash offering: ~55.2M shares at $0.7751/share plus pre-funded warrants for 11.5M shares. Cryptocurrency offering: pre-funded warrants for ~223.6M shares with investors tendering ATH tokens.
Cash PIPE: $51.7M gross from 66.7M shares at $0.7751; Crypto PIPE: $292.7M notional ($173.3M discounted) in ATH tokens.
Predictive Oncology approves 1-for-15 reverse stock split to meet Nasdaq bid price
Stockholders approved 1:15 reverse split on Sep 19, 2025; effective Sep 30, 2025.
Predictive Oncology raises ~$413K in private placement of 543,544 shares at $0.76/share
Sold 543,544 shares at $0.76 each to accredited investor; gross proceeds ~$413K.
Predictive Oncology Q2 loss $0.22/share; revenue $2.7K; ChemoFx U.S./EU launch expected Q4 2025
Loss from continuing ops ~$2.0M; diluted EPS -$0.22 vs -$0.53 YoY.
Predictive Oncology granted Nasdaq extension through Dec 8, 2025 to regain listing compliance
Nasdaq Hearing Panel extended continued listing deadline to December 8, 2025.
Nasdaq notifies Predictive Oncology of bid price deficiency; 180-day cure period to Jan 5, 2026
Received Nasdaq letter on July 8, 2025 for failure to maintain minimum $1.00 bid price over 30 consecutive days.
Predictive Oncology enters $10M standby equity purchase agreement with YA II PN
Company can sell up to $10M of common stock at 96% of lowest 3-day VWAP over 36 months.
Predictive Oncology receives Nasdaq delisting notice for failure to meet equity requirement
Nasdaq notified Predictive Oncology June 9 of delisting for failing to meet $2.5M stockholders' equity requirement.
Predictive Oncology ends merger talks with Renovaro; no binding agreement signed
POAI decided to discontinue discussions with RENB regarding the proposed merger.
Predictive Oncology ends merger talks with Renovaro; LOI expired March 31, 2025
POAI discontinued discussions with Renovaro (RENB) regarding proposed merger; LOI expired March 31, 2025.
Revenue of $1.6M essentially flat YoY; loss from continuing ops of $10.8M.
Predictive Oncology agrees to be acquired by Renovaro for $3.00/share in preferred stock
POAI shareholders to receive 1 share of Renovaro preferred stock per POAI share, redeemable for $3.00 after 18 months.
Stockholders' equity $1,966,969 as of Sept 30, 2024, below Nasdaq's $2.5M minimum.
Predictive Oncology Q3 loss of $2.3M; revenue down 49%; exploring strategic alternatives
Loss from continuing ops of ~$2.3M on revenue of $345,686, down from $676,626 YoY.
Predictive Oncology receives Nasdaq bid price deficiency notice; has until Mar 18, 2025 to cure
Nasdaq notified on Sept 19, 2024 that POAI common stock closed below $1.00 for 30 consecutive business days.
Predictive Oncology Q2 net loss $3.2M on revenue $0.3M; enters biomarker discovery market
Net loss of $3.2M ($0.68 per share) on revenue of $278,722, down 43% YoY from $490K.
Predictive Oncology ovarian cancer ML study results positive; to be presented at ASCO 2024
Retrospective study with UPMC Magee-Womens Hospital used 160 multi-omic ML models to predict ovarian cancer survival.
Predictive Oncology Q1 net loss $4.2M on revenue $0.4M; cash $5.2M, EPS -$1.04
Net loss of ~$4.2M, wider than $3.5M loss in Q1 2023; diluted EPS -$1.04 vs -$0.86.
Predictive Oncology enters ATM sales agreement for up to $3.7M of common stock with H.C. Wainwright
Entered ATM Sales Agreement with H.C. Wainwright for up to $3,696,000 of common stock.
On February 2, 2024, Predictive Oncology Inc. (the “Company”) and Pamela Bush, Ph.D., MBA, the Company’s Chief Business Officer, agreed that Dr. Bush will leave the Company effective February 15, 2024.
Josh Blacher of Danforth, an experienced biotech executive who specializes in strategic finance and corporate development, has been named as the Company’s Interim Chief Financial Officer.
Bob Myers, the Chief Financial Officer, Corporate Secretary and Compliance Officer of Predictive Oncology Inc. (the "Company"), notified the Company of his intent to resign from the Company effective September 30, 2023 (the "Transition Date").
On May 2, 2023, David S. Smith, JD, resigned as a director of Predictive Oncology Inc. (the “Company”), effective immediately.
Effective May 2, 2023, the Board elected Dr. Veena Rao to the Board as a Class III director.
the Board of Directors of the Company appointed Pamela Bush, Ph.D., MBA, as Chief Business Officer.
On January 30, 2023, the Board of Directors of Predictive Oncology Inc. (the “Company”) appointed Pamela Bush, Ph.D., MBA, age 49, as Chief Business Officer.
Effective November 29, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected Matthew J. Hawryluk, Ph.D., to the Board as a Class II director.
Effective October 19, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected David S. Smith, JD, to the Board as a Class III director.
the Company appointed Raymond F. Vennare, age 70, to succeed Mr. Engle as Chief Executive Officer
J. Melville Engle would be retiring as the Company’s Chief Executive Officer and as Chairman and a member of the Company’s board of directors, effective October 31, 2022.
the Board of Directors of the Company appointed Raymond F. Vennare as Chairman of the Board, effective upon Mr. Engle’s retirement.
Max materiality 0.95 · Median 0.60 · Most common event other_material